Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
ABSTRACT Background Real‐world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited. Methods We evaluated outcomes of patients with newly‐diagnosed AML treated with HMA + VEN50 with either posaconazole (n =...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wiley
2025-06-01
|
| Seri Bilgileri: | eJHaem |
| Konular: | |
| Online Erişim: | https://doi.org/10.1002/jha2.70049 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|